Provided herein are methods of treating heart failure, chronic kidney disease (CKD) or hypertension, in a companion animal, comprising administering to a companion animal in need thereof a therapeutically effective amount of a compound that inhibits a sodium-dependent glucose transporter (SGLT) or a prodrug thereof. In some embodiments, the compound that inhibits an SGLT is bexagliflozin.

Provided herein are methods of treating heart failure, chronic kidney disease (CKD) or hypertension, in a companion animal, comprising administering to a companion animal in need thereof a therapeutically effective amount of a compound that inhibits a sodium-dependent glucose transporter (SGLT) or a prodrug thereof. In some embodiments, the compound that inhibits an SGLT is bexagliflozin.

An amorphous form of a nitrogen-containing tricyclic compound and a use thereof, a pharmaceutical composition containing the compound in the amorphous form, and the use of the compound in the amorphous form or the pharmaceutical composition in the preparation of a drug for preventing, treating or alleviating FXR-mediated diseases in a patient.

Cannabidiol derivatives and medical use thereof, in particular to compounds represented by general formula (I), or stereoisomers, solvates, metabolites, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of the substituents in general formula (I) are the same as those in the description.

##STR00001##

The invention relates to processes for preparing benzoprostacyclin analogues and intermediates prepared from the process, and the benzoprostacyclin analogues prepared therefrom. The invention also relates to cyclopentenone intermediates in racemic or optically active form.

The present invention relates to a pharmaceutical composition in the form of a storage-stable solution for the parenteral administration of ultrashort-effective β-adrenoreceptor antagonists, comprising a) an ultrashort-effective β-adrenoreceptor antagonist and/or a pharmaceutically acceptable salt thereof, b) water, and c) a cyclodextrin and/or a functional cyclodextrin derivative. The composition according to the invention has high stability, even without the presence of additional adjuvants.

Microstructure arrays and methods for using and manufacturing the arrays are described.

A degradation product produced by degrading a composition containing a hyaluronic acid and a protein with a protease has a pain relieving effect, a joint function ameliorating effect, a cholesterol-lowering effect, a hypoglycemic effect and a diastolic blood pressure-lowering effect.

A degradation product produced by degrading a composition containing a hyaluronic acid and a protein with a protease has a pain relieving effect, a joint function ameliorating effect, a cholesterol-lowering effect, a hypoglycemic effect and a diastolic blood pressure-lowering effect.

In various embodiments, the present invention provides pharmaceutical compositions and methods for treating cardiovascular-related disease.